))
Interview with Transcend Therapeutics CEO Blake Mandell
Manage episode 381792734 series 2793637
Content provided by David E. Williams. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David E. Williams or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
My father's PhD advisor at Harvard was Timothy Leary, so I've always had an interest in psychedelics. After decades in the regulatory wilderness, psychedelic products like MDMA are now being developed to treat mental health disorders.
But if these drugs are approved there will be a new problem: patient access. The treatments generally require many hours of highly trained mental health provider time per patient. That's not going to scale.
Blake Mandell is CEO of Transcend Therapeutics, which seeks to address these challenges with a non-hallucinogenic MDMA analogue. That should mean much less need for clinical supervision of patients and should also take away patient concerns about tripping.
Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.
193 episodes
Share
